Literature DB >> 7353200

Polymorphonuclear neutrophil function in malignant lymphomas and effects of splenectomy.

V Von Fliedner, V Salvatori, D J Higby, L Stutzman, B H Park.   

Abstract

Granulocyte (PMN) directional locomotion (migration) in vitro and in vivo, resting nitroblue tetrazolium (NBT)-reduction and adherence to nylon wool of polymorphonuclear neutrophils (PMN) were assayed in 7 patients with Hodgkin's disease (HD) and in 11 patients with non-Hodgkin's lymphoma (NHL) prior to therapy. In most patients with HD, NBT-reduction was increased and in all directional locomotion was markedly decreased both in vitro and in vivo. In addition to being depressed, accumulation of PMN into skin chambers in patients with HD correlated with the peripheral blood count (r = 0.95). In vitro directional migration of PMN in NHL was depressed in half the patients, but increased in the in vivo assay. After splenectomy, PMN-adherence tended to increase and NBT-reduction to decrease. These findings are compatible with a constant cellular defect of PMN in HD, whereas in NHL abnormal PMN function is more likely mediated by extracellular factors. Abnormal PMN function may correlate with clinical susceptibility to infection in malignant lymphomas.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7353200     DOI: 10.1002/1097-0142(19800201)45:3<469::aid-cncr2820450310>3.0.co;2-2

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  3 in total

1.  Defective activation of neutrophils after splenectomy.

Authors:  P N Foster; R P Bolton; K L Cotter; M S Losowsky
Journal:  J Clin Pathol       Date:  1985-10       Impact factor: 3.411

Review 2.  The role of the spleen in leukemias and lymphomas including Hodgkin's disease.

Authors:  R Maurer
Journal:  Experientia       Date:  1985-02-15

3.  Defective neutrophil mobilization to skin chambers in cancer patients.

Authors:  G Frumento; E Bonvini; F Minervini; F Dallegri; F Patrone; C Sacchetti
Journal:  J Cancer Res Clin Oncol       Date:  1984       Impact factor: 4.553

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.